Vaximm Ag

Ratiopharm Gmbh

Biogenerix Ag

Vaximm Gmbh

Nec Oncolmmunity As

Heinz Lubenau

Marco Springer

Walter Hinderer

David A Zopf

Holger Siede

Renate Janssen

The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain ofwith at least one DNA molecule comprising at least one expression cassette encoding at least one antigen or at least one fragment thereof; (b) characterizing at least one transformed cell clone obtained in step (a); and (c) selecting at least one of the transformed cell clone(s) characterized in step (b) and further characterizing said at least one selected transformed cell clone. The present invention further relates to a DNA vaccine obtainable by the method according to the present invention.

Process for the production of a DNA vaccine for cancer immunotherapy

The present invention relates to an attenuated strain ofcomprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain offor use in the treatment of cancer.

PD-L1 targeting DNA vaccine for cancer immunotherapy

The present invention relates to an attenuated strain ofcomprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein for use in cancer immunotherapy, wherein the cancer is characterized by VEGF receptor protein expressing cancer cells. The present invention further relates to an attenuated strain ofcomprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein for use in cancer immunotherapy, wherein the cancer is characterized by VEGF receptor protein expressing cancer cells, and wherein the cancer is selected from the group consisting of glioblastoma, carcinoid cancer, kidney cancer, particularly renal cell carcinoma, thyroid cancer, lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC), breast cancer, ovarian cancer, prostate cancer, gastrointestinal cancer, particularly colorectal cancer, more particularly colon cancer, and skin cancer, particularly melanoma. The present invention further relates to an attenuated strain ofcomprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein for use in cancer immunotherapy in a patient comprising at least one VEGF receptor protein expressing cancer cell.

VEGFR-2 targeting immunotherapy approach

The present invention relates to an attenuated strain ofcomprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain ofcomprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain ofcomprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.

VEGFR-2 targeting DNA vaccine for combination therapy

The present invention relates to an attenuated mutant strain ofcomprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain ofin cancer immunotherapy.

Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

The present invention relates to an attenuated mutant strain ofcomprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain ofin cancer immunotherapy.

MSLN targeting DNA vaccine for cancer immunotherapy

The present invention relates to an attenuated mutant strain ofcomprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain ofin cancer immunotherapy.

DNA vaccine for use in pancreatic cancer patients

The present invention relates to an attenuated mutant strain ofcomprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain ofin cancer immunotherapy.

[object Object]

This invention relates to a novel method for growing attenuated mutantstrains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing saidstrain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutantstrains obtainable by said method and to an attenuated mutantstrain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.

Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.

Methods of preparing a liquid formulation of G-CSF

The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has received or will receive radiation or chemotherapy treatment. The methods and compositions of the invention can further be used to prevent, alleviate and treat the myelosuppressive effects such therapies.

Growing community of inventors

Neustadt an der Weinstrasse, Germany

Heinz Lubenau